Earnings Call Insights: Coloplast A/S (OTCPK:CLPBF) Q1 2025 CEO Kristian Villumsen highlighted 8% organic growth and a reported EBIT margin of 27% for Q1 2025, which aligned with expectations.

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates ...

Investing.com -- Shares of Coloplast (CSE:COLOb) climbed 3.5% as the medical device company reported first-quarter revenue in line with consensus expectations and earnings per share (EPS ...

Ladies and gentlemen, welcome to the Coloplast A/S Q1 2024-'25 Earnings Release Conference Call. I'm Valentina, the Chorus Call operator. [Operator Instructions] The conference must not be ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Coloplast delivered 8% organic growth and an EBIT margin1 of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...